SK284282B6 - Použitie sibutramínových analógov na znižovanie hladín tukov - Google Patents

Použitie sibutramínových analógov na znižovanie hladín tukov Download PDF

Info

Publication number
SK284282B6
SK284282B6 SK320-99A SK32099A SK284282B6 SK 284282 B6 SK284282 B6 SK 284282B6 SK 32099 A SK32099 A SK 32099A SK 284282 B6 SK284282 B6 SK 284282B6
Authority
SK
Slovakia
Prior art keywords
sibutramine
formula
analog
compound
medicament
Prior art date
Application number
SK320-99A
Other languages
English (en)
Slovak (sk)
Other versions
SK32099A3 (en
Inventor
Peter Finian Kelly
Stephen Paul Jones
Original Assignee
Abbott Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co. Kg filed Critical Abbott Gmbh & Co. Kg
Publication of SK32099A3 publication Critical patent/SK32099A3/sk
Publication of SK284282B6 publication Critical patent/SK284282B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Fats And Perfumes (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Analogue/Digital Conversion (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SK320-99A 1996-09-25 1997-09-15 Použitie sibutramínových analógov na znižovanie hladín tukov SK284282B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9619961.7A GB9619961D0 (en) 1996-09-25 1996-09-25 Medical treatment
PCT/EP1997/005040 WO1998013034A1 (en) 1996-09-25 1997-09-15 Use of sibutramine analogues to lower lipid levels

Publications (2)

Publication Number Publication Date
SK32099A3 SK32099A3 (en) 1999-12-10
SK284282B6 true SK284282B6 (sk) 2004-12-01

Family

ID=10800447

Family Applications (1)

Application Number Title Priority Date Filing Date
SK320-99A SK284282B6 (sk) 1996-09-25 1997-09-15 Použitie sibutramínových analógov na znižovanie hladín tukov

Country Status (26)

Country Link
US (1) US6187820B1 (he)
EP (1) EP0973511B1 (he)
JP (1) JP4143126B2 (he)
KR (1) KR100573333B1 (he)
CN (1) CN1173696C (he)
AT (1) ATE239459T1 (he)
AU (1) AU724645B2 (he)
BG (1) BG64472B1 (he)
BR (1) BR9711411A (he)
CA (1) CA2266378C (he)
CZ (1) CZ291879B6 (he)
DE (1) DE69721833T2 (he)
DK (1) DK0973511T3 (he)
ES (1) ES2199354T3 (he)
GB (1) GB9619961D0 (he)
HU (1) HU224711B1 (he)
IL (1) IL128820A (he)
NO (1) NO991424L (he)
NZ (1) NZ334550A (he)
PL (1) PL190017B1 (he)
PT (1) PT973511E (he)
RU (1) RU2197959C2 (he)
SK (1) SK284282B6 (he)
TR (1) TR199900648T2 (he)
UA (1) UA63916C2 (he)
WO (1) WO1998013034A1 (he)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
AU2007200334B8 (en) * 1998-08-24 2010-10-21 Sepracor, Inc. Methods of using and compositions comprising dopamine reuptake inhibitors
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6046242A (en) * 1998-11-27 2000-04-04 Basf Aktiengesellschaft Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
WO2000056308A1 (en) * 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Prevention of cardiovascular disease
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
FR2814678B1 (fr) * 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
NZ538966A (en) * 2002-10-05 2006-11-30 Hanmi Pharm Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate
WO2004096202A1 (en) * 2003-04-28 2004-11-11 Cipla Limited Pharmaceutical formulation comprising anti-obesity agent and acidulant
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
US20050032908A1 (en) * 2003-08-04 2005-02-10 Beckman Kristen M. Methods for treating metabolic syndrome
KR100618176B1 (ko) 2004-12-02 2006-09-01 휴먼팜 주식회사 시부트라민 주석산염, 이의 제조 방법 및 이를 포함하는약학적 조성물
KR20060080818A (ko) * 2005-01-06 2006-07-11 씨제이 주식회사 시부트라민의 술폰산염
WO2006073292A1 (en) * 2005-01-06 2006-07-13 Cj Corporation Inorganic acid salts of sibutramine
KR20060080817A (ko) 2005-01-06 2006-07-11 씨제이 주식회사 시부트라민의 디카복실산염
KR20060093564A (ko) * 2005-02-22 2006-08-25 종근당바이오 주식회사 무수 시부트라민 말산염 및 이의 제조 방법
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
KR100814384B1 (ko) * 2006-02-10 2008-03-18 대화제약 주식회사 시부트라민 염을 함유하는 약학 조성물 및 이의 제조방법
US8604244B2 (en) 2010-07-02 2013-12-10 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
EP2066329B1 (en) 2006-09-15 2017-09-06 Reviva Pharmaceuticals, Inc. Synthesis, methods of using, and compositions of cyclobutylmethylamines
KR20080046601A (ko) * 2006-11-22 2008-05-27 에스케이케미칼주식회사 보관안정성이 우수한 시부트라민 함유 포접복합체
WO2010082216A2 (en) * 2008-12-08 2010-07-22 Matrix Laboratories Ltd Novel salts of sibutramine and their crystal forms
SG11201403165SA (en) 2011-12-30 2014-08-28 Reviva Pharmaceuticals Inc Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment

Also Published As

Publication number Publication date
ATE239459T1 (de) 2003-05-15
JP2001500883A (ja) 2001-01-23
CA2266378C (en) 2007-02-13
IL128820A (he) 2001-10-31
RU2197959C2 (ru) 2003-02-10
HUP9903823A3 (en) 2000-07-28
PL190017B1 (pl) 2005-10-31
BG64472B1 (bg) 2005-04-30
CZ291879B6 (cs) 2003-06-18
US6187820B1 (en) 2001-02-13
BR9711411A (pt) 1999-08-17
SK32099A3 (en) 1999-12-10
PT973511E (pt) 2003-08-29
KR20000048567A (ko) 2000-07-25
DK0973511T3 (da) 2003-08-25
NO991424D0 (no) 1999-03-24
CN1173696C (zh) 2004-11-03
HUP9903823A2 (hu) 2000-06-28
NO991424L (no) 1999-03-24
HU224711B1 (en) 2006-01-30
DE69721833T2 (de) 2003-12-24
IL128820A0 (en) 2000-01-31
GB9619961D0 (en) 1996-11-13
AU4774197A (en) 1998-04-17
AU724645B2 (en) 2000-09-28
KR100573333B1 (ko) 2006-04-24
BG103249A (en) 1999-09-30
EP0973511B1 (en) 2003-05-07
UA63916C2 (uk) 2004-02-16
TR199900648T2 (xx) 1999-06-21
JP4143126B2 (ja) 2008-09-03
ES2199354T3 (es) 2004-02-16
CA2266378A1 (en) 1998-04-02
WO1998013034A1 (en) 1998-04-02
EP0973511A1 (en) 2000-01-26
PL332367A1 (en) 1999-09-13
DE69721833D1 (de) 2003-06-12
NZ334550A (en) 2000-09-29
CZ93299A3 (cs) 2000-07-12
CN1231605A (zh) 1999-10-13

Similar Documents

Publication Publication Date Title
SK284282B6 (sk) Použitie sibutramínových analógov na znižovanie hladín tukov
SK31999A3 (en) Use of sibutramine analogues to prevent the development of diabetes
SK32199A3 (en) Use of sibutramine analogues for producing drug to lower uric acid levels and pharmaceutical composition containing mentioned analogues
US6376552B1 (en) Treatment of gallstones
US6355685B1 (en) Method of treating anxiety disorders
SK285308B6 (sk) Liečivo na liečenie porúch spánku
US6372797B1 (en) Treatment of menstrual function
US6380260B1 (en) Treatment to lower platelet adhesiveness
US6803387B1 (en) Treatment of neuropathic pain or fibromyalgia
US6403650B1 (en) Treatment of pulmonary hypertension
US6288125B1 (en) Treatment of hiatial hernia
US6433020B1 (en) Treatment of cardiovascular disease
US20030008897A1 (en) Method of controlling weight gain associated with therapeutic drugs
US20020132856A1 (en) Treatment of premenstrual syndrome
MXPA99002633A (en) Use of sibutramine analogues to lower lipid levels
SK13392001A3 (sk) Použitie zlúčeniny a farmaceutická kompozícia ju obsahujúca